Table 1.
Baseline characteristics of 87 metastatic gastric cancer patients treated with trastuzumab-based chemotherapy (T + CT) and 1111 patients treated with standard chemotherapy (CT).
| Characteristic | Treatment Group | p-Value | |
|---|---|---|---|
| T + CT (N = 87) |
CT (N = 1111) |
||
| Age at diagnosis | |||
| <55 | 10 (11.5) | 204 (18.4) | 0.140 * |
| 55–64 | 31 (35.6) | 285 (25.7) | |
| 65–74 | 31 (35.6) | 371 (33.4) | |
| 75 | 15 (17.2) | 251 (22.6) | |
| Median | 67 | 66 | |
| Sex | |||
| Women | 23 (26.4) | 402 (36.2) | 0.067 |
| Men | 64 (73.6) | 709 (63.8) | |
| Year of diagnosis | |||
| 2011 | 15 (17.2) | 243 (21.9) | 0.674 * |
| 2012 | 15 (17.2) | 156 (14.0) | |
| 2013 | 10 (11.5) | 174 (15.7) | |
| 2014 | 21 (24.1) | 176 (15.8) | |
| 2015 | 14 (16.1) | 200 (18.0) | |
| 2016 | 12 (13.8) | 162 (14.6) | |
| Surgery | |||
| No | 62 (71.3) | 862 (77.6) | 0.176 |
| Yes | 25 (28.7) | 249 (22.4) | |
| MCS score | |||
| 0–2 | 54 (62.1) | 669 (60.2) | 0.716 * |
| 3–5 | 27 (31.0) | 349 (31.4) | |
| 6–8 | 4 (4.6) | 73 (6.6) | |
| ≥9 | 2 (2.3) | 20 (1.8) | |
T: trastuzumab; CT: standard chemotherapy; MCS: Multisource Comorbidity Score; * Chi-square test for trend.